

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*

(A joint stock limited company established in the People's Republic of China)

(Stock Code: 8197)

CLARIFICATION ANNOUNCEMENT
PLACING OF NEW H-SHARES UNDER GENERAL MANDATE

Reference is made to the Company's announcement dated 24 May 2016 ("Announcement") relating to the Placing. Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

For the avoidance of doubt, the Placing Price, which shall be determined by agreement between the Company and the Placing Agent, shall not be, unless otherwise agreed between the parties:

- (a) at a discount at or more than 20% to the higher of:
 - (i) the closing price of H-Shares on the date on which the Placing Price is agreed;and
 - (ii) the average closing price of H-Shares during the 5 consecutive trading days immediately prior to the date on which the Placing Price is agreed.
- (b) less than the par value of the H-Share.

The Board will make an announcement upon the Placing Price is determined pursuant to the Listing Rules.

By Order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Jilin, the PRC, 27 May 2016

As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun and Cao Yang and the Company's independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

** for identification purposes only*